This recording will focus on Bacillus Calmette-Guérin–unresponsive (BCG-U) non-muscle-invasive bladder cancer (NMIBC). BCG-U NMIBC remains to be a therapeutic challenge due to its substantial risk of progression to muscle-invasive bladder cancer (MIBC), and requires further management including radical cystectomy (RC). In this context, different intravesical and systemic therapies (immunotherapies, gene therapies and drug-delivery devices) emerge as promising alternatives to delay or potentially avoid RC.
In this recording, we will discuss a clinical case of a patient with high-grade BCG-U NMIBC, and examine the different therapeutic options including intravesical and systemic therapies. We will also analyse the efficacy data, as well as the benefit-risk balance including risk of progression and adverse events.
Speakers:
- Prof. Dr. E.N. Xylinas (FR)
- Dr. G. Marcq (FR)
- Prof. S. Shariat (AT)
- Dr. F. Soria (IT)
This recording is brought to you in collaboration with the EAU Section of Oncological Urology. Acknowledgment This activity is supported by an educational grant from our industry partner – Ferring Pharmaceuticals, with no involvement in the programme or speaker selection. https://ferringusa.com/
🌟 Important info: The recording of this webinar is not EU-ACME accredited. Missed the live session? Earn 1 CME point by completing our online e-course at: https://uroweb.org/education-events/education?page=1&type=e-course. Don’t miss this opportunity! 🎓💡